Delivery Order 75D30123D18241-75D30123F00002
- Not listed
- This federal contract award was made by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) to Duke University's Office of Research Administration Division. The $263,144.00 award is a delivery order under the CDC's Clinical Immunization Safety Assessment (CISA) master indefinite-delivery, indefinite-quantity (IDIQ) contract, which has a potential value of $86 million through September 2028. Under this contract, Duke University provides clinical research...
- The U.S. Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a $608,717 delivery order contract to Duke University's Office of Research Administration Division to provide Clinical Immunization Safety Assessment (CISA) services. The contract has a period of performance ending on September 30, 2020 and is not associated with a set-aside. This delivery order is part of a larger CISA indefinite delivery, indefinite quantity (IDIQ) contract with a...
- Duke University's Office of Research Administration was awarded a delivery order under the 2023 Clinical Immunization Safety Assessment (CISA) Base IDIQ contract by the Centers for Disease Control and Prevention (CDC) Pittsburgh on September 28, 2023. This cost-plus-no-fee contract, valued at $874,846, supports immunization safety assessment services and will be performed in Durham, North Carolina, with an ultimate completion date of September 27, 2028. The award was made through a competitive...
- This is a federal contract award from the Centers for Disease Control and Prevention (CDC) to Duke University, a private university and non-profit organization, to provide clinical research and immunization safety assessment services. The contract is a delivery order under the Clinical Immunization Safety Assessment (CISA) indefinite delivery, indefinite quantity (IDIQ) contract vehicle. The contract has a ceiling value of $465,451.00 and was awarded on September 29, 2015, with a completion date...
- This is a federal contract award from the Centers for Disease Control and Prevention (CDC) to Duke University. The contract was awarded under the Clinical Immunization Safety Assessment (CISA) indefinite delivery, indefinite quantity (IDIQ) vehicle. The contract has a ceiling value of $713,975.00 and was awarded on September 29, 2016, with an ultimate completion date of October 28, 2019. The contract is for the delivery of clinical research and immunization safety assessment services. The...
- Duke University Office of Research Administration Division was awarded a $499,784 firm fixed price delivery order against its Clinical Immunization Safety Assessment (CISA) indefinite-delivery/indefinite-quantity (IDIQ) contract with the Centers for Disease Control and Prevention (CDC). The delivery order is for a CISA SHINGRIX lead study to be performed in Durham, North Carolina by November 2022. Duke University holds the CISA IDIQ contract with CDC, valued at up to $86 million through...
- This is a federal contract award to Duke University, a leading research institution, by the Centers for Disease Control and Prevention (CDC). The contract, valued at $1,893,456.00, is for the provision of COVID-19 clinical immunization safety assessment (CISA) services in Cincinnati. The contract is a delivery order issued under the CISA indefinite delivery, indefinite quantity (IDIQ) contract vehicle, which enables the CDC to obtain these critical services. The contract does not have a...
- Duke University's Office of Research Administration received a delivery order contract valued at $1.07M under the Clinical Immunization Safety Assessment (CISA) master IDIQ vehicle from the CDC Pittsburgh on September 29, 2017. This cost-no-fee contract, which extended through September 28, 2022, supported COVID response efforts and was performed at Duke's Durham, North Carolina location. The award was made on a competitive basis with no set-aside designation. The Clinical Immunization Safety...
- Duke University was awarded a $2,031,493.71 firm fixed price contract by the Centers for Disease Control and Prevention (CDC) to support Topic 2 of the FY 2020 COVID-19 Broad Agency Announcement. Performance will take place in Atlanta, GA through December 31, 2022. As prime contractor, Duke University will provide clinical research and immunization safety assessment services to the CDC under this award. The Institute for Medical Research, Inc., a nonprofit research organization supporting work...
- This federal contract was awarded by the Centers for Disease Control and Prevention (CDC), part of the Department of Health and Human Services, to Duke University to provide Clinical Immunization Safety Assessment (CISA) services. The contract is a Delivery Order under the CISA master IDIQ contract, which has a potential value of $86 million through September 2028. Two task orders have been awarded to date - one valued at $875,045 for CISA services in Durham, NC from September 2023 to...
- 75D30123D18241Indefinite Delivery Contract
- 75D30123D18241-75D30123F00002Delivery Order
The Centers for Disease Control and Prevention (CDC) awarded Duke University a $2,180,450.00 Indefinite Delivery Indefinite Quantity (IDIQ) contract for the 2023 Clinical Immunization Safety Assessment (CISA) base contract. This cost-no-fee delivery order contract will provide clinical research and immunization safety assessment services to the CDC through September 27, 2026. The contract was awarded on an unrestricted basis, without any set-aside designations. As a prime contractor, Duke University's Office of Research Administration Division will be responsible for delivering these services to the CDC, which supports the agency's public health mission. Duke University has a history of conducting federal contract and grant work across a range of disciplines for various government agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00001 | Supplemental Agreement for work within scope | $2.4k | 8/5/24 | |
| Not listed | Not listed | $2.2m | 9/27/23 |